121099-59-0

Upstream product

• 4885-02-3 Dichloromethyl methyl ether 
• 121099-61-4 7-(4-fluorophenyl)-7-(2-hydroxy-3,4,6-trimethylphenyl)heptanoic acid 
• 697-82-5 2,3,5-trimethylphenol 
• 13159-14-3 (E)-7-phenyl-6-heptenoic acid 
• 103187-28-6 7-(4-fluorophenyl)-7-hydroxyheptanoic acid 

Downstream Products

• 121099-97-6 methyl 7-(4-fluorophenyl)-7-<2-hydroxy-5-(methoxymethyl)-3,4,6-trimethylphenyl>heptanoate 
• 121099-96-5 7-(4-Fluoro-phenyl)-7-(2-hydroxy-5-methoxymethyl-3,4,6-trimethyl-phenyl)-heptanoic acid 
• 121099-67-0 methyl (R)-7-(4-flurophenyl)-7-(3-formyl-6-methoxy-2,4,5-trimethylphenyl)heptanoate 
• 121099-62-5 7-(4-fluorophenyl)-7-<2-hydroxy-5-(hydroxymethyl)-3,4,6-trimethylphenyl>heptanoic acid 

Relevant academic research and scientific papers

Process for preparing diphenylmethane compounds

A diphenylmethane compound (III) can be produced in a good yield by allowing a phenol compound (I) to react with a stilbene compound (II) in the presence of methanesulfonic acid STR1

Synthesis and Thromboxane A2/Prostaglandin H2 Receptor Antagonistic Activity of Phenol Derivatives

Consideration of possible structural similarities between thromboxane A2 and the hydroquinone form of (R)-(+)-7-(3,5,6-trimethyl-1,4-benzoquinon-2-yl)-7-phenylheptanoic acid (R-(+)-AA-2414) led to the development of a new series of thromboxane A2/prostagl

Phenol derivatives, their production and use

Novel phenol derivatives of the general formula: STR1 wherein R1, R2, R3, R4, R5, X, Y and n are as defined in the specification, which have therapeutic and prophylactic activities against cerebral, c